Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| RWIPA-10-1001 | Nov 2025 | 99.9% | Freedom Diagnostics | Endotoxin | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. Ipamorelin is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Riptide Wellness sell Ipamorelin?
Riptide Wellness has 1 COA on file for Ipamorelin but no active price listing is currently tracked.
Is Riptide Wellness's Ipamorelin third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Riptide Wellness's Ipamorelin, with the most recent showing 99.9% purity. Riptide Wellness holds an overall trust grade of B (84/100) across all 35 COAs on file.
What is Riptide Wellness's trust grade for Ipamorelin?
Riptide Wellness has an overall Disclosed Labs trust grade of B (84/100), computed from 35 COAs across all peptides. The most recent Ipamorelin COA was issued by Freedom Diagnostics.
Where is the cheapest Ipamorelin?
As of the latest data, Peptide Supply Co. offers Ipamorelin at $2.70/mg — compare with Riptide Wellness's listing. See the full Ipamorelin price comparison.
Is Ipamorelin legal to buy?
Ipamorelin is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs